+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Phase II Trial"

From
From
From
From
Clinical Trials: Psychedelic Therapeutics - Product Thumbnail Image

Clinical Trials: Psychedelic Therapeutics

  • Report
  • July 2024
  • 32 Pages
  • Global
From
Clinical Trials - Precision and Personalized Medicine - Product Thumbnail Image

Clinical Trials - Precision and Personalized Medicine

  • Report
  • July 2023
  • 45 Pages
  • Global
From
From
Clinical Trials - Impact of COVID-19 and Long COVID - Product Thumbnail Image

Clinical Trials - Impact of COVID-19 and Long COVID

  • Report
  • May 2023
  • 60 Pages
  • Global
From
Global Cancer Vaccine Market & Clinical Trial Insight 2025 - Product Thumbnail Image

Global Cancer Vaccine Market & Clinical Trial Insight 2025

  • Clinical Trials
  • September 2018
  • 700 Pages
  • Global
From
Loading Indicator

Phase II Clinical Trials are a critical step in the drug development process. They are designed to evaluate the safety and efficacy of a drug or medical device in a larger group of people than Phase I trials. The Phase II trial market is a subset of the larger clinical trial market, and is composed of pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic institutions. Phase II trials are typically conducted in multiple countries, and involve a larger number of participants than Phase I trials. They are designed to assess the efficacy of a drug or medical device in a larger population, and to identify any potential side effects. The results of Phase II trials are used to determine whether a drug or medical device should proceed to Phase III trials. Some of the companies in the Phase II trial market include Pfizer, Merck, Novartis, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Eli Lilly, and Sanofi. CROs such as Parexel, Quintiles, and Covance also play a significant role in the Phase II trial market. Show Less Read more